{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:09Z","timestamp":1789723989568,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1094816"],"award-info":[{"award-number":["OPP1094816"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-quality, representative serological surveys allow direct estimates of immunity profiles to inform vaccination strategies but can be costly and logistically challenging. Leveraging residual serum samples is one way to increase their feasibility. We subsampled 9854 residual sera from a 2016 national HIV survey in Zambia and tested these specimens for anti-measles and anti-rubella virus IgG antibodies using indirect enzyme immunoassays. We demonstrate innovative methods for sampling residual sera and analyzing seroprevalence data, as well as the value of seroprevalence estimates to understand and control measles and rubella. National measles and rubella seroprevalence for individuals younger than 50\u00a0years was 82.8% (95% CI 81.6, 83.9%) and 74.9% (95% CI 73.7, 76.0%), respectively. Despite a successful childhood vaccination program, measles immunity gaps persisted across age groups and districts, indicating the need for additional activities to complement routine immunization. Prior to vaccine introduction, we estimated a rubella burden of 96 congenital rubella syndrome cases per 100,000 live births. Residual samples from large-scale surveys can reduce the cost and challenges of conducting serosurveys, and multiple pathogens can be tested. Procedures to access quality specimens, ensure ethical approvals, and link sociodemographic data can improve the timeliness and value of results.<\/jats:p>","DOI":"10.1038\/s41598-022-14493-3","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T12:05:57Z","timestamp":1655467557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Leveraging a national biorepository in Zambia to assess measles and rubella immunity gaps across age and space"],"prefix":"10.1038","volume":"12","author":[{"given":"Andrea C.","family":"Carcelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Chilumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mutale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gershom","family":"Chongwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwaka","family":"Monze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mulundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Nkamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis. D.","family":"Mwansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Mulenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale A.","family":"Rhoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Hayford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Mutembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"14493_CR1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.15585\/mmwr.mm6945a6","volume":"69","author":"MK Patel","year":"2020","unstructured":"Patel, M. K. Progress toward regional measles elimination: Worldwide, 2000\u20132019. MMWR Morb. Mortal. Wkly. Rep. 69, 1700 (2020).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"14493_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0140-6736(21)01337-4","volume":"398","author":"K Causey","year":"2021","unstructured":"Causey, K. et al. Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: A modelling study. The Lancet 398, 522\u2013534 (2021).","journal-title":"The Lancet"},{"key":"14493_CR3","unstructured":"World Health Organization. At Least 80 Million Children Under One at Risk of Diseases Such as Diphtheria, Measles and Polio as COVID-19 Disrupts Routine Vaccination Efforts, Warn Gavi, WHO and UNICEF. https:\/\/www.who.int\/news\/item\/22-05-2020-at-least-80-million-children-under-one-at-risk-of-diseases-such-as-diphtheria-measles-and-polio-as-covid-19-disrupts-routine-vaccination-efforts-warn-gavi-who-and-unicef (2020)."},{"key":"14493_CR4","volume-title":"Measles and Rubella Strategic Framework: 2021\u20132030","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Measles and Rubella Strategic Framework: 2021\u20132030 (World Health Organization, 2020)."},{"key":"14493_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1371\/journal.pmed.1001404","volume":"10","author":"FT Cutts","year":"2013","unstructured":"Cutts, F. T., Izurieta, H. S. & Rhoda, D. A. Measuring coverage in MNCH: Design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys. PLoS Med. 10, 123 (2013).","journal-title":"PLoS Med."},{"key":"14493_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/infdis\/jiy137","volume":"218","author":"AK Winter","year":"2018","unstructured":"Winter, A. K. et al. Benefits and challenges in using seroprevalence data to inform models for measles and rubella elimination. J. Infect. Dis. 218, 355\u2013364 (2018).","journal-title":"J. Infect. Dis."},{"key":"14493_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3201\/eid1902.120301","volume":"19","author":"A Minetti","year":"2013","unstructured":"Minetti, A. et al. Lessons and challenges for measles control from unexpected large outbreak, Malawi. Emerg. Infect. Dis. 19, 202\u2013209 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"14493_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-03043-4","volume":"589","author":"AN Sbarra","year":"2021","unstructured":"Sbarra, A. N. et al. Mapping routine measles vaccination in low- and middle-income countries. Nature 589, 415\u2013419 (2021).","journal-title":"Nature"},{"key":"14493_CR9","doi-asserted-by":"publisher","first-page":"28506","DOI":"10.1073\/pnas.2011529117","volume":"117","author":"NB Masters","year":"2020","unstructured":"Masters, N. B. et al. Fine-scale spatial clustering of measles nonvaccination that increases outbreak potential is obscured by aggregated reporting data. PNAS 117, 28506\u201328514 (2020).","journal-title":"PNAS"},{"key":"14493_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/tmi.12737","volume":"21","author":"FT Cutts","year":"2016","unstructured":"Cutts, F. T. & Hanson, M. Seroepidemiology: An underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Trop. Med. Int. Health 21, 1086\u20131098 (2016).","journal-title":"Trop. Med. Int. Health"},{"key":"14493_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/aje\/kwy114","volume":"187","author":"AK Winter","year":"2018","unstructured":"Winter, A. K. et al. Revealing measles outbreak risk with a nested immunoglobulin G serosurvey in Madagascar. Am. J. Epidemiol. 187, 2219\u20132226 (2018).","journal-title":"Am. J. Epidemiol."},{"key":"14493_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149160","volume":"11","author":"E Vynnycky","year":"2016","unstructured":"Vynnycky, E. et al. Using seroprevalence and immunisation coverage data to estimate the global burden of congenital rubella syndrome, 1996\u20132010: A systematic review. PLoS ONE 11, e0149160 (2016).","journal-title":"PLoS ONE"},{"key":"14493_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1473-3099(17)30421-8","volume":"17","author":"F Trentini","year":"2017","unstructured":"Trentini, F., Poletti, P., Merler, S. & Melegaro, A. Measles immunity gaps and the progress towards elimination: A multi-country modelling analysis. Lancet Infect. Dis. 17, 1089\u20131097 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"14493_CR14","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1016\/j.vaccine.2018.04.036","volume":"36","author":"DN Durrheim","year":"2018","unstructured":"Durrheim, D. N., Orenstein, W. A. & Schluter, W. W. Assessing population immunity for measles elimination: The promise and peril of serosurveys. Vaccine 36, 4001\u20134003 (2018).","journal-title":"Vaccine"},{"key":"14493_CR15","unstructured":"World Health Organization. Guidelines on the Use of Serosurveys in support of Measles and Rubella Elimination. https:\/\/www.who.int\/immunization\/monitoring_surveillance\/burden\/laboratory\/serosurvey\/en\/ (2016)."},{"key":"14493_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0035-9203(00)90347-X","volume":"94","author":"S Kebede","year":"2000","unstructured":"Kebede, S. et al. Maternal rubella-specific antibody prevalence in Ethiopian infants. Trans. R. Soc. Trop. Med. Hyg. 94, 333\u2013340 (2000).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"14493_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3201\/eid2407.171928","volume":"24","author":"BF Arnold","year":"2018","unstructured":"Arnold, B. F., Scobie, H. M., Priest, J. W. & Lammie, P. J. Integrated serologic surveillance of population immunity and disease transmission. Emerg. Infect. Dis. 24, 1188\u20131194 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"14493_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.abe1916","volume":"371","author":"S Uyoga","year":"2021","unstructured":"Uyoga, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 371, 79\u201382 (2021).","journal-title":"Science"},{"key":"14493_CR19","unstructured":"World Health Organization. Guidance For Managing Ethical Issues In Infectious Disease Outbreak. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/250580\/9789241549837-eng.pdf%3Bjsessionid=CC0C33101B31B6A491E8E111DFDBC848?sequence=1 (2016)."},{"key":"14493_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1017\/S0021932000019738","volume":"24","author":"VK Pillai","year":"1992","unstructured":"Pillai, V. K. & Conaway, M. Immunisation coverage in Lusaka, Zambia: Implications of the social setting. J. Biosoc. Sci. 24, 201\u2013209 (1992).","journal-title":"J. Biosoc. Sci."},{"key":"14493_CR21","unstructured":"Zambia Statistics Agency, Ministry of Health (MOH) Zambia & ICF. Zambia Demographic and Health Survey 2018. https:\/\/dhsprogram.com\/pubs\/pdf\/FR361\/FR361.pdf (2019)."},{"key":"14493_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1086\/519169","volume":"196","author":"WJ Moss","year":"2007","unstructured":"Moss, W. J. et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and Uninfected Zambian children: An observational study. J. Infect. Dis. 196, 347\u2013355 (2007).","journal-title":"J. Infect. Dis."},{"key":"14493_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"14493_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12879-020-4806-5","volume":"20","author":"ML Mazaba","year":"2020","unstructured":"Mazaba, M. L., Siziya, S., Monze, M. & Cohen, D. Epidemiology of acute rubella infection in Zambia during the pre-vaccination period (2005\u20132016) as a baseline for monitoring rubella epidemiology in the post-rubella vaccine introduction era. BMC Infect. Dis. 20, 101 (2020).","journal-title":"BMC Infect. Dis."},{"key":"14493_CR25","unstructured":"World Health Organization. Immunization, Vaccines and Biologicals: Surveillance for Vaccine Preventable Diseases. https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/timeseries\/tsincidencemeasles.html (2020)."},{"key":"14493_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067639","volume":"8","author":"J Lessler","year":"2013","unstructured":"Lessler, J. & Metcalf, C. J. E. Balancing evidence and uncertainty when considering rubella vaccine introduction. PLoS ONE 8, e67639 (2013).","journal-title":"PLoS ONE"},{"key":"14493_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(12)61215-X","volume":"380","author":"FT Cutts","year":"2012","unstructured":"Cutts, F. T., Metcalf, C. J. E., Lessler, J. & Grenfell, B. T. Rubella vaccination: must not be business as usual. The Lancet 380, 217\u2013218 (2012).","journal-title":"The Lancet"},{"key":"14493_CR28","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/sim.8897","volume":"40","author":"CE Utazi","year":"2021","unstructured":"Utazi, C. E., Nilsen, K., Pannell, O., Dotse-Gborgbortsi, W. & Tatem, A. J. District-level estimation of vaccination coverage: Discrete vs continuous spatial models. Stat. Med. 40, 2197\u20132211 (2021).","journal-title":"Stat. Med."},{"key":"14493_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sste.2018.01.003","volume":"25","author":"CE Utazi","year":"2018","unstructured":"Utazi, C. E., Afuecheta, E. O. & Nnanatu, C. C. A Bayesian latent process spatiotemporal regression model for areal count data. Spatial Spatio-temp. Epidemiol. 25, 25\u201337 (2018).","journal-title":"Spatial Spatio-temp. Epidemiol."},{"key":"14493_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1473-3099(20)30442-4","volume":"21","author":"J Schenk","year":"2021","unstructured":"Schenk, J. et al. Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: A systematic review and meta-analysis. Lancet Infect. Dis. 21, 286\u2013295 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"14493_CR31","doi-asserted-by":"publisher","unstructured":"Institute for Health Metrics and Evaluation (IHME). Low- and Middle-Income Country MCV1 Coverage Geospatial Estimates 2000\u20132019. https:\/\/doi.org\/10.6069\/VFWJ-JF14 (2020).","DOI":"10.6069\/VFWJ-JF14"},{"key":"14493_CR32","doi-asserted-by":"publisher","first-page":"30118","DOI":"10.1073\/pnas.1920986117","volume":"117","author":"P Bosetti","year":"2020","unstructured":"Bosetti, P. et al. Heterogeneity in social and epidemiological factors determines the risk of measles outbreaks. Proc. Natl. Acad. Sci. USA 117, 30118\u201330125 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"14493_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.vaccine.2018.12.012","volume":"37","author":"SA Truelove","year":"2019","unstructured":"Truelove, S. A. et al. Characterizing the impact of spatial clustering of susceptibility for measles elimination. Vaccine 37, 732\u2013741 (2019).","journal-title":"Vaccine"},{"key":"14493_CR34","unstructured":"Ministry of Health, Zambia. Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2016: Final Report. https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2019\/03\/ZAMPHIA-Final-Report__2.26.19.pdf (2019)."},{"key":"14493_CR35","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.vaccine.2019.02.037","volume":"37","author":"K Hayford","year":"2019","unstructured":"Hayford, K. et al. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey. Vaccine 37, 2387\u20132393 (2019).","journal-title":"Vaccine"},{"key":"14493_CR36","unstructured":"Lumley, T. Survey: Analysis of Complex Survey Samples. R package version 4.0. (2020)."},{"key":"14493_CR37","unstructured":"World Health Organization & UNICEF. WHO\/UNICEF Estimates of National Immunization Coverage, Estimates for 1980 to 2019. https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/timeseries\/tswucoveragemcv1.html (2020)."},{"key":"14493_CR38","unstructured":"World Health Organization. Data, Statistics and Graphics|4.1 Summary of Measles-Rubella Supplementary Immunization Activities, 2000\u20132021. https:\/\/www.who.int\/teams\/regulation-prequalification\/eul\/immunization-vaccines-and-biologicals (2020)."},{"key":"14493_CR39","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(12)60522-4","volume":"379","author":"E Simons","year":"2012","unstructured":"Simons, E. et al. Assessment of the 2010 global measles mortality reduction goal: Results from a model of surveillance data. Lancet 379, 2173\u20132178 (2012).","journal-title":"Lancet"},{"key":"14493_CR40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1126\/science.aaa3438","volume":"347","author":"S Takahashi","year":"2015","unstructured":"Takahashi, S. et al. Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science 347, 1240\u20131242 (2015).","journal-title":"Science"},{"key":"14493_CR41","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1186\/s12916-019-1413-7","volume":"17","author":"S Funk","year":"2019","unstructured":"Funk, S. et al. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Med. 17, 1413 (2019).","journal-title":"BMC Med."},{"key":"14493_CR42","unstructured":"R Core Team. A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, 2020)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14493-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:29:19Z","timestamp":1669354159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14493-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14493"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14493-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10217"}}